Genmab Reports 28.2-Month Median Survival in Combination Trial
Genmab reported 28.2-month median survival in a trial combining petosemtamab with pembrolizumab.
Genmab reported 28.2-month median survival in a trial combining petosemtamab with pembrolizumab.